Asia-Pacific SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) - Industry Trends and Forecast to 2030.
Asia-Pacific SJS/TEN Treatment Market Analysis and Insights
The treatment market for stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is relatively small due to the rarity of these diseases.
Asia-Pacific SJS/TEN treatment market is dominated by drugs, as drugs are the main form of treatment for these conditions. Corticosteroids, intravenous immunoglobulin (IVIG), and antibiotics are the most commonly used medications in the treatment of SJS/TEN.
Asia-Pacific SJS/TEN treatment market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.6% in the forecast period of 2023 to 2030 and is expected to reach USD 5,257.31 million by 2030 from USD 2,741.31 million in 2022.
Asia-Pacific SJS/TEN treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Paediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others)
|
|
Countries Covered
|
China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific
|
|
Market Players Covered
|
3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others
|
Market Definition
Stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin conditions that usually result from severe drug reactions. These conditions cause the top layer of skin to separate from the layers below, resulting in painful blisters and sores that can cover much of the body. SJS affects a smaller part of the skin, while TEN affects a larger part of the skin.
The definition of the Asia-Pacific SJS/TEN treatment market refers to products and services designed to manage and treat these conditions. There are drugs, therapies, and other treatments in the market that can help relieve SJS/TEN symptoms and improve patients' quality of life. The drug market for the treatment of SJS/TEN includes a number of drugs that are used to relieve symptoms and treat the underlying cause.
Asia-Pacific SJS/TEN Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:
Drivers
-
Increasing prevalence and incidence of SJS/TEN
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions involving the skin and mucous membranes. SJS and TEN are considered two ends of the disease spectrum, with SJS being the milder form and TEN being the more severe form. A characteristic feature of these conditions is the separation of the epidermis (the outer layer of the skin) from the dermis (the layer below the skin) due to a strong immune reaction.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious skin diseases characterized by the separation of the epidermis from the dermis. The incidence of SJS/TEN has been reported to be around 1 per million people per year. However, in recent years there has been increased concern about the incidence and prevalence of SJS/TEN.
-
Advances in Drug Development for SJS/TEN Treatment
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions that require prompt and aggressive treatment. Although there is currently no specific medication or treatment that can cure SJS/TEN, advances in drug development have led to better treatment strategies and treatment outcomes for affected patients. But there are various clinical trials going on for drug development for SJS/TEN treatment.
Restraint
-
High Cost Associated With the Treatment of SJS/TEN
One of the main reasons why SJS/TEN treatment is expensive is the need for intensive and long-term treatment. Patients with SJS/TEN often require hospitalization in specialized burn units, where they receive 24-hour care from a team of health professionals including dermatologists, ophthalmologists, and critical care specialists. Hospitalization can last several weeks and in severe cases even months. This can lead to high hospital bills and other related costs such as transportation, accommodation, and meals.
Opportunity
-
Developing Effective and Safe Treatment for SJS/TEN
Stem cell transplantation is a new approach that aims to replace damaged skin and mucous membranes with healthy tissue. Autologous stem cell transplantation, where stem cells are taken from the patient's skin and grown in culture before being transplanted back into the damaged area, has shown promising results in small studies.
Challenge
- Stringent Government Regulations for Approval of a Treatment for SJS/TEN
The strict government regulations for the approval of SJS/TEN treatments are related to the complex and rigorous process that pharmaceutical companies and their drugs must go through to obtain approval for an SJS/TEN treatment from regulatory agencies such as the US Food and Drug Administration. (FDA) or the European Medicines Agency (EMA).
The approval process for a new drug usually involves several stages of clinical trials in humans to assess the drug's safety and effectiveness.
Recent Developments
- In June 2020, BD, a leading Asia-Pacific medical technology company announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio. This will help the company to expand and grow in the market.
- In January 2019, Mölnlycke Health Care AB. acquires MandJ Airlaid Products A/S to further strengthen its wound care capabilities. In connection with the acquisition, MandJ, and its employees will be an integral part of Mölnlycke. The acquisition will improve Mölnlycke's security of supply for the air-laid material needed to produce advanced wound dressings and help grow the wound care business by accelerating innovation and product development in existing and future products. This will help the company to expand and grow in the market.
Asia-Pacific SJS/TEN Treatment Market Scope
Asia-Pacific SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Asia-Pacific SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.
Treatment
- Medications
- Support Care
- Ointments
- Hospitalization
- Isolation
- Others
On the basis of treatment, the Asia-Pacific SJS/TEN treatment market is segmented into medications, support care, hospitalization, isolation, ointments, and others.
Diagnosis
- Physical Exam
- Medical History
- Skin Biopsy
- Blood Test
- Cultures
- Others
On the basis of diagnosis, the Asia-Pacific SJS/TEN treatment market is segmented into physical exam, skin biopsy, medical history, blood test, cultures, and others.
Cause
- Specific Treatment
- Infection
- Others
On the basis of cause, the Asia-Pacific SJS/TEN treatment market is segmented into specific treatment, infection, and others.
Route of Administration
- Oral
- Parenteral
- Topical
- Others
On the basis of route of administration, the Asia-Pacific SJS/TEN treatment market is segmented into oral, parenteral, topical, and others.
Drug Type
- Branded
- Generic
On the basis of drug type, the Asia-Pacific SJS/TEN treatment market is segmented into branded and generic.
Therapy Type
- Monotherapy
- Combination Therapy
On the basis of therapy type, the Asia-Pacific SJS/TEN treatment market is segmented into combination therapy and monotherapy.
Patient Type
- Pediatric
- Adult
- Geriatric
On the basis of patient type, the Asia-Pacific SJS/TEN treatment market is segmented into geriatric, adult, and pediatric.
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Center
- Homecare Setting
- Others
On the basis of end user, the Asia-Pacific SJS/TEN treatment market is segmented into hospitals, specialty clinics, ambulatory surgical center, homecare setting, and others.
Distribution Channel
- Direct Tenders
- Retail Pharmacies
- Others
On the basis of distribution channel, the Asia-Pacific SJS/TEN treatment market is segmented into retail pharmacies, direct tenders, and others.
Asia-Pacific SJS/TEN Treatment Market Regional Analysis/Insights
Asia-Pacific SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.
The countries covered in this market report are China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, and Rest of Asia-Pacific.
China is expected to dominate due to the increasing investment in R&D is expected to boost market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific SJS/TEN Treatment Market Share Analysis
Asia-Pacific SJS/TEN treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific SJS/TEN treatment market.
Some of the major players operating in the Asia-Pacific SJS/TEN treatment market are 3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others.
SKU-